L3VLUP
ProSign in

ALLO in the 13F filings

Allogene Therapeutics Inc · CUSIP 019770106

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022
Quarter end
31 Dec 2022
the date the book describes
Filed
14 Feb 2023
latest of these filings; the earliest 13 Feb 2023
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2022 and Q4 2022; 1 listed it in both
Shares listed
4,080,163
combined, among listed positions
Reported value
$26m
combined, at the quarter end

Managers listing ALLO in Q4 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Woodline Partners LP2,921,462$18m0.25%Trimmed-1,604,96014 Feb 2023 (the filing on sec.gov)
ExodusPoint Capital Management LP1,158,701$7.3m0.11%Addedn.a.13 Feb 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2022 to Q4 2022, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2023 to 1 in Q2 2025

Tracked managers listing it, at least.

0358102019202020212022202320242025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ALLO by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20182$121mn.a.n.a.
Q1 20192$159mn.a.n.a.
Q2 20192$216mn.a.n.a.
Q3 20192$233mn.a.n.a.
Q4 20193$248mn.a.n.a.
Q1 20202$232mn.a.n.a.
Q2 20209$785mn.a.n.a.
Q3 20209$702mn.a.n.a.
Q4 20205$462mn.a.n.a.
Q1 20217$666mn.a.n.a.
Q2 20218$321mn.a.n.a.
Q3 20215$302mn.a.n.a.
Q4 20213$10mn.a.n.a.
Q1 20223$6.5mn.a.n.a.
Q2 20223$79mn.a.n.a.
Q3 20224$60mn.a.n.a.
Q4 20222$26mn.a.n.a.
Q1 20232$11mn.a.n.a.
Q2 20232$27mn.a.n.a.
Q3 20233$18mn.a.n.a.
Q4 20232$11m11
Q1 20243$15m21
Q2 20243$27m30
Q3 20244$37m21
Q4 20243$24m02
Q1 20252$24m20
Q2 20251$13m01

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ALLO and GILD →ALLO and AMGN →ALLO and ARGX →Choose a stock to compare with ALLO →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ALLO, latest filings →Back to the 13F Explorer →